Molbio Diagnostics IPO: ₹939.7 cr book-built raise comprising ₹200 cr fresh issue & ₹739.7 cr OFS, listed Aug 17 at ₹980/share (21% premium).

IPO / ECM 17 Aug 2026· ₹939.696 cr · Completed· ✓ Verified

The IPO comprised 24.8 lakh shares (₹200 cr) at fresh issuance and 91.66 lakh shares (₹739.7 cr) offer-for-sale by existing shareholders including Exxora Trading LLP (promoter holding 41.23%), Dr. Chandrasekhar Bhaskaran Nair (promoter), India Business Excellence Fund III (Motilal Oswal-backed, 12.66%), and V Sciences Investments (Temasek-backed, 8.93%). The issue was priced at ₹807/share (upper band). Anchor allocation (Aug 7) raised ₹281.5 cr from 33 institutional investors, including Goldman Sachs, BlackRock, Mirae, Nippon India MF, ICICI Prudential, Kotak MF, Tata MF, WhiteOak, and Bajaj/HDFC Life Insurance. Public subscription opened Aug 10–12 with allotment finalized Aug 13. Listing…

Why it mattersMixed IPO dynamics: 186.39x QIB over-subscription vs. 12.96x retail demand reflects strong institutional conviction in POC diagnostics valuations; OFS-heavy structure (79% of total) limited fresh capital availability for expansion-R&D and Centre of Excellence scaling contingent on working capital and operational cashflows.
CounselKhaitan & Co, Cyril Amarchand Mangaldas, Hogan Lovells Cadwalader
SectorPharma & Healthcare
Value₹939.696 cr
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals